Assessment of Fracture Risk (Q57711517)

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

World-wide projections for hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Assessment of fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Effectiveness of Bone Density Measurement for Predicting Osteoporotic Fractures in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Hip fracture in women without osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

The population burden of fractures originates in women with osteopenia, not osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Identification of osteopenic women at high risk of fracture: the OFELY study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Risk communication and shared decision making in the care of patients with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Communicating data about the benefits and harms of treatment: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Absolute fracture risk reporting in clinical practice: A physician-centered survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Development and use of FRAX in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Algorithm for the management of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

FRAX and the assessment of fracture probability in men and women from the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Interpretation and use of FRAX in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

International variations in hip fracture probabilities: implications for risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Secular trends in the incidence of hip and other osteoporotic fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Effects of FRAX® Model Calibration on Intervention Rates: A Simulation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

The US FRAX filter: avoiding confusion or hindering progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

The potential impact of new National Osteoporosis Foundation guidance on treatment patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Fracture burden in relation to low bone mineral density and FRAX(®) probability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Screening for osteoporosis: U.S. preventive services task force recommendation statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Guidance for the adjustment of FRAX according to the dose of glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Glucocorticoid osteoporosis--mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Rheumatoid arthritis, corticosteroid therapy and hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Fracture risk with intermittent high-dose oral glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

A reference standard for the description of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Updated data on proximal femur bone mineral levels of US adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Clinical utility of spine bone density in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: Derivation and validation of a hybrid system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Spine-hip T-score difference predicts major osteoporotic fracture risk independent of FRAX(®): a population-based report from CAMOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-011-0093-9

Skeletal site bone mineral density heterogeneity in women and men

21 January 2018

1 reference

12 December 2020

Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks

1 reference

12 December 2020

Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis

1 reference

12 December 2020

Fractures in rheumatoid arthritis: an evaluation of associated risk factors

1 reference

12 December 2020

Single-Site vs Multisite Bone Density Measurement for Fracture Prediction

1 reference

12 December 2020

Osteoporosis: recent advances in pathogenesis and treatment.

1 reference

12 December 2020

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

12 December 2020

The diagnosis of osteoporosis

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

1 reference

12 December 2020

Fracture risk assessment without bone density measurement in routine clinical practice.

1 reference

12 December 2020

A longitudinal study of the effect of spinal degenerative disease on bone density in the elderly

1 reference

12 December 2020

Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores

1 reference

12 December 2020

Discordance in patient classification using T-scores

1 reference

12 December 2020

A comparative study of using non-hip bone density inputs with FRAX®.

1 reference

12 December 2020

Predictive Value of BMD for Hip and Other Fractures

1 reference

12 December 2020

Drugs for pre-osteoporosis: prevention or disease mongering?

1 reference

12 December 2020